Oppenheimer Maintains Outperform on HCA Healthcare, Raises Price Target to $345
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on HCA Healthcare (NYSE:HCA) and raises the price target from $330 to $345.
April 29, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on HCA Healthcare and raises the price target from $330 to $345.
The increase in the price target by a reputable analyst suggests a positive outlook on HCA Healthcare's stock, likely due to strong fundamentals or growth prospects. This endorsement could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100